Champions Oncology Inc.

11.06-0.2300-2.04%Vol 14.41K1Y Perf 61.43%
Apr 16th, 2021 16:00 DELAYED
BID11.09 ASK11.20
Open11.46 Previous Close11.29
Pre-Market- After-Market11.06
 - -  - -%
Target Price
15.00 
Analyst Rating
Strong Buy 1.00
Potential %
35.62 
Finscreener Ranking
★★★★+     56.86
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★     48.00
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     49.69
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap148.09M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
54.06 
Earnings Date
11th Mar 2021

Today's Price Range

10.9811.46

52W Range

6.8014.68

5 Year PE Ratio Range

-30.201.04K

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-2.30%
1 Month
-11.45%
3 Months
-1.60%
6 Months
22.75%
1 Year
61.43%
3 Years
169.76%
5 Years
203.01%
10 Years
-8.75%

TickerPriceChg.Chg.%
CSBR11.06-0.2300-2.04
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
1.20
1.20
0.42
0.82
-
Leverage Ratio 3.70
ProfitabilityValueIndustryS&P 500US Markets
47.00
-2.00
0.90
-33.20
-3.52
RevenueValueIndustryS&P 500US Markets
39.22M
2.93
22.71
27.47
Earnings HistoryEstimateReportedSurprise %
Q03 20210.010.05400.00
Q02 20210.010.00-100.00
Q01 20210.020.01-50.00
Q04 20200.01-0.17-1 800.00
Q03 20200.020.0350.00
Q02 2020-0.020.02200.00
Q01 20200.03-0.06-300.00
Q04 20190.03-0.02-166.67
Earnings Per EndEstimateRevision %Trend
4/2021 QR0.010.00-
4/2021 QR0.01-66.67Negative
4/2021 FY0.06200.00Positive
4/2022 FY0.2033.33Positive
Next Report Date-
Estimated EPS Next Report0.01
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume14.41K
Shares Outstanding13.39M
Trades Count647
Dollar Volume182.57K
Avg. Volume31.47K
Avg. Weekly Volume16.98K
Avg. Monthly Volume30.37K
Avg. Quarterly Volume32.75K

Champions Oncology Inc. (NASDAQ: CSBR) stock closed at 11.06 per share at the end of the most recent trading day (a -2.04% change compared to the prior day closing price) with a volume of 14.41K shares and market capitalization of 148.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 143 people. Champions Oncology Inc. CEO is Ronnie Morris.

The one-year performance of Champions Oncology Inc. stock is 61.43%, while year-to-date (YTD) performance is 2.5%. CSBR stock has a five-year performance of 203.01%. Its 52-week range is between 6.8 and 14.68, which gives CSBR stock a 52-week price range ratio of 54.06%

Champions Oncology Inc. currently has a PE ratio of -94.90, a price-to-book (PB) ratio of 19.37, a price-to-sale (PS) ratio of 3.87, a price to cashflow ratio of 51.40, a PEG ratio of 2.32, a ROA of -5.90%, a ROC of -11.48% and a ROE of -21.71%. The company’s profit margin is -3.52%, its EBITDA margin is 0.90%, and its revenue ttm is $39.22 Million , which makes it $2.93 revenue per share.

Of the last four earnings reports from Champions Oncology Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Champions Oncology Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Champions Oncology Inc. is Strong Buy (1), with a target price of $15, which is +35.62% compared to the current price. The earnings rating for Champions Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Champions Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Champions Oncology Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.48, ATR14 : 0.64, CCI20 : -79.52, Chaikin Money Flow : -0.13, MACD : -0.04, Money Flow Index : 38.51, ROC : -3.83, RSI : 46.33, STOCH (14,3) : 32.47, STOCH RSI : 0.35, UO : 48.09, Williams %R : -67.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Champions Oncology Inc. in the last 12-months were: Abba David Poliakoff (Sold 0 shares of value $-32 100 ), David Sidransky (Sold 0 shares of value $-91 002 ), Philip Breitfeld (Sold 0 shares of value $-15 210 ), Philip Breitfeld (Sold 31 443 shares of value $356 976 ), Scott R. Tobin (Option Excercise at a value of $109 200)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Champions Oncology Inc.

Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

CEO: Ronnie Morris

Telephone: +1 201 808-8400

Address: One University Plaza, Hackensack 07601, NJ, US

Number of employees: 143

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

46%54%

Bearish Bullish

58%42%

News

Stocktwits